Myeloid-derived suppressor cells (MDSC) and fibroblasts located in the tumor stroma suppress CD8+ T cells and may reduce the effectiveness of PD-1 blocking in both types of esophageal cancer, thereby affecting the effectiveness of immunotherapy [10,11]. Here, CD8A is linked to neoplasm.